Multivariate Analysis of Prognostic Factors Among 2,313 Patients With Stage III Melanoma: Comparison of Nodal Micrometastases Versus Macrometastases
Charles M. Balch(The University of Texas MD Anderson Cancer Center), Vernon K. Sondak(Advanced Dermatology), Martín C. Mihm(Harvard University), John F. Thompson(Melanoma Institute Australia), Merrick I. Ross(Johns Hopkins University), Alexander M.M. Eggermont(University Medical Center Utrecht), Stanley P. L. Leong(California Pacific Medical Center), Jeffrey E. Gershenwald(The University of Texas MD Anderson Cancer Center), Kelly M. McMasters(University of Louisville), Timothy M. Johnson(University of Michigan), Donald L. Morton(University of California, Los Angeles), Natale Cascinelli, David R. Byrd(University of Washington), Seng-Jaw Soong(Johns Hopkins University), Alistair J. Cochran(Western Infirmary), John M. Kirkwood(UPMC Hillman Cancer Center), Shouluan Ding(Johns Hopkins University), Daniel G. Coit(Memorial Sloan Kettering Cancer Center)
Cited by 410
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k
Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
|CA A Cancer Journal for Clinicians|2017|2.3k
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
|New England Journal of Medicine|2018|1.9k